| Drug Name |
Everolimus |
| Drug ID |
BADD_D00858 |
| Description |
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein. |
| Indications and Usage |
Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. |
| Marketing Status |
Prescription |
| ATC Code |
L01EG02; L04AA18 |
| DrugBank ID |
DB01590
|
| KEGG ID |
D02714
|
| MeSH ID |
D000068338
|
| PubChem ID |
6442177
|
| TTD Drug ID |
D0K3QS
|
| NDC Product Code |
65727-064; 65129-1324; 0078-0626; 0078-0620; 0054-0482; 67877-719; 52076-6247; 0078-0594; 0054-0470; 49884-159; 0378-3097; 49884-158; 68254-6234; 65727-063; 49884-160; 70377-013; 71796-012; 49884-119; 0378-3098; 70225-1103; 52076-6253; 70377-010; 0078-0422; 0054-0497; 0078-0414; 0054-0471; 0378-0006; 0093-7767; 0078-0627; 52076-6234; 62227-013; 0093-7766; 0078-0628; 71052-559; 67877-720; 0378-0005; 65727-046; 49884-125; 0054-0472; 0054-0604; 0078-0566; 49884-283; 0378-0007; 67877-721; 67877-718; 51991-823; 0054-0481; 17404-1027; 0078-0417; 0078-0415; 0093-7768; 49884-127; 70377-011; 62227-018; 70377-012; 0054-0480; 62227-019; 51991-821; 51991-822; 0078-0567; 0378-3096; 51991-824 |
| Synonyms |
Everolimus | SDZ RAD | RAD, SDZ | SDZ-RAD | 40-O-(2-hydroxyethyl)-rapamycin | RAD 001 | 001, RAD | RAD001 | Certican | Afinitor |
